ImmunoPrecise Antibodies Ltd. (IPA)
NASDAQ: IPA · Real-Time Price · USD
1.010
+0.064 (6.73%)
At close: Jun 18, 2025, 4:00 PM
1.000
-0.010 (-0.99%)
After-hours: Jun 18, 2025, 7:58 PM EDT
ImmunoPrecise Antibodies Stock Forecast
Stock Price Forecast
The 2 analysts that cover ImmunoPrecise Antibodies stock have a consensus rating of "Strong Buy" and an average price target of $4, which forecasts a 296.04% increase in the stock price over the next year. The lowest target is $3 and the highest is $5.
Price Target: $4 (+296.04%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 11, 2025.
Analyst Ratings
The average analyst rating for ImmunoPrecise Antibodies stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +395.05% | Apr 11, 2025 |
| Benchmark | Benchmark | Buy Reiterates $3 | Buy | Reiterates | $3 | +197.03% | Apr 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $5 | Strong Buy | Maintains | $7 → $5 | +395.05% | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +593.07% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $7 | Strong Buy | Maintains | $9 → $7 | +593.07% | Dec 11, 2024 |
Financial Forecast
Revenue This Year
25.66M
from 24.52M
Increased by 4.67%
Revenue Next Year
29.30M
from 25.66M
Increased by 14.15%
EPS This Year
-0.64
from -1.06
EPS Next Year
-0.11
from -0.64
Financial currency is CAD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 27.4M | 30.5M | 40.2M | |||
| Avg | 25.7M | 29.3M | 38.7M | |||
| Low | 24.2M | 28.4M | 37.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 11.9% | 18.7% | 37.3% | |||
| Avg | 4.7% | 14.1% | 32.1% | |||
| Low | -1.3% | 10.8% | 28.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.26 | -0.12 | 0.02 |
| Avg | -0.64 | -0.11 | 0.02 |
| Low | -0.99 | -0.11 | 0.02 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.